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Abstract
Leptin, a peripheral signal synthetized by the adipocyte to regulate energy metabolism, can also be produced by placenta,
where it may work as an autocrine hormone. We have previously demonstrated that leptin promotes proliferation and
survival of trophoblastic cells. In the present work, we aimed to study the molecular mechanisms that mediate the survival
effect of leptin in placenta. We used the human placenta choriocarcinoma BeWo and first trimester Swan-71 cell lines, as
well as human placental explants. We tested the late phase of apoptosis, triggered by serum deprivation, by studying the
activation of Caspase-3 and DNA fragmentation. Recombinant human leptin added to BeWo cell line and human placental
explants, showed a decrease on Caspase-3 activation. These effects were dose dependent. Maximal effect was achieved at
250 ng leptin/ml. Moreover, inhibition of endogenous leptin expression with 2 mM of an antisense oligonucleotide, reversed
Caspase-3 diminution. We also found that the cleavage of Poly [ADP-ribose] polymerase-1 (PARP-1) was diminished in the
presence of leptin. We analyzed the presence of low DNA fragments, products from apoptotic DNA cleavage. Placental
explants cultivated in the absence of serum in the culture media increased the apoptotic cleavage of DNA and this effect
was prevented by the addition of 100 ng leptin/ml. Taken together these results reinforce the survival effect exerted by
leptin on placental cells. To improve the understanding of leptin mechanism in regulating the process of apoptosis we
determined the expression of different intermediaries in the apoptosis cascade. We found that under serum deprivation
conditions, leptin increased the anti-apoptotic BCL-2 protein expression, while downregulated the pro-apoptotic BAX and
BID proteins expression in Swan-71 cells and placental explants. In both models leptin augmented BCL-2/BAX ratio.
Moreover we have demonstrated that p53, one of the key cell cycle-signaling proteins, is downregulated in the presence of
leptin under serum deprivation. On the other hand, we determined that leptin reduced the phosphorylation of Ser-46 p53
that plays a pivotal role for apoptotic signaling by p53. Our data suggest that the observed anti-apoptotic effect of leptin in
placenta is in part mediated by the p53 pathway. In conclusion, we provide evidence that demonstrates that leptin is a
trophic factor for trophoblastic cells.
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Introduction
Apoptosis is a naturally occurring event in placental cells. It
plays an important role in placenta growth, turnover, senescence
and parturition. Apoptotic mechanisms are also associated with
the fusion of cytotrophoblast and the differentiation to multinu-
cleate syncytium. Regulators of apoptosis are now considered to
have a major role in maintaining the integrity of villous
trophoblast [1]. In pregnancies complicated by pre-eclampsia
[2,3] and intra-uterine growth restriction (IUGR) [4], apoptosis is
increased in villous trophoblast and are associated with increased
formation of syncytial knots [5]. In placental villi, cell turnover is
tightly regulated and apoptosis may be induced following cell
damage as result of hypoxia or oxidative stress.
The p53 protein is a master transcription factor that increases in
response to different stress stimuli such as heat shock, hypoxia,
osmotic shock and DNA damage, leading to growth arrest,
apoptosis and DNA repair [6]. Upon these cellular stresses, p53 is
phosphorylated and acetylated at multiple sites to activate
downstream target genes [7], protein levels of p53 are negatively
regulated by MDM2, an E3 ubiquitin ligase, via a negative
feedback loop that is essential in determining cell survival [8].
Phosphorylation of p53 at Ser-15 leads to the dissociation of
MDM2, and p53 degradation is inhibited [9]. It was previously
shown that phosphorylation of Ser-46 on p53 contributes to the
expression of p53-regulated apoptosis-inducing protein 1
(p53AIP1) [10]. Ser-46 phosphorylation also contributes to the
preferential transactivation of other pro-apoptotic genes [11].
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Amongst its many functions, p53 promotes transcription of p21, a
cell cycle inhibitor, and BAX, a pro-apoptotic mitochondrial pore
protein [12].
Another family of proteins, the BCL-2, function as major
regulator of the intrinsic apoptotic pathway [13]. Following a
death stimulus, the multi-domain pro-apoptotic family members,
BAX and BAK proteins form homo- and hetero-oligomers
triggering mitochondrial outermembrane permeability and the
release of inter-membrane space proteins such as Cytochrome c
and activation of the downstream apoptotic pathway [14]. The
effects of BAX are attenuated by the anti-apoptotic BCL-2 [15].
The BH3-only family members serve as sensors of cellular
damage. As result of posttranslational modifications these proteins
translocate to the mitochondria, where they activate BAX and
BAK. BID is a BH3-only pro-death BCL-2 family molecule that
has the ability to interact with the multi-domain pro-death
molecules BAX or BAK. This feature constitutes the basis of how
the BH3-only molecules may induce apoptosis by either inacti-
vating the anti-death molecules and/or directly activating a multi-
domain pro-death molecule [16].
All these factors present in the villous trophoblast indicate a
potential role in regulating cell turnover [17]. The study of the
molecular mechanisms that regulate placental cell death is
important for understanding normal development and a variety
of diseases of the placenta.
Leptin, a small non-glycosilated pleiotropic peptide of 146
aminoacid residues (16 kDa), was found to be secreted by adipose
tissue [18]. Leptin modulates satiety and energy homeostasis [19].
Evidence shows leptin has a key role implantation and embryo
development [20,21,22]. The synthesis and secretion of leptin and
its functional receptors by trophoblast cells have been widely
demonstrated [23,24], suggesting leptin may act through a
paracrine or autocrine mechanism. Plasma leptin concentrations
are significantly elevated in pregnant women as compared with
those in age and body mass index-matched nonpregnant women
[23,25], and drops sharply after delivery [26]. The expression of
leptin in the placenta is tightly regulated by hCG, cAMP and 17b-
estradiol [27,28,29,30]. Deregulation of leptin metabolism and/or
leptin function in the placenta may be implicated in the
pathogenesis of various disorders during pregnancy, such as
recurrent miscarriage, gestational diabetes, intrauterine growth
restriction, and preeclampsia [31,32].
Previous results of our group have demonstrated that leptin
stimulates the process of proliferation and protein synthesis, and
inhibits apoptosis in human trophoblastic cells [33,34,35,36,37].
In this work we aimed to study the mechanisms of leptin effect on
trophoblast survival. We analyzed the expression of some
regulators of cell apoptosis and found that leptin decreased the
cleavage of Caspase-3 and Poly [ADP-ribose] polymerase 1
(cPARP-1) proteins. On the other hand leptin increased the BCL-
2/BAX relationship and diminished the level of Bid. We analyzed
p53 protein expression, the master key regulator of death
signaling. We found that leptin produced a reduction in p53
level. Moreover we determined a decrease in the phosphorylation
of Ser-46 p53 that plays a pivotal role for apoptotic signaling by
p53. All these results reinforce the notion of an anti-apoptotic
effect of leptin on trophoblastic cells and unravel some of the
mechanisms involved.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all subjects and all
study procedures were approved by ethical review committees at
the Virgen Macarena University Hospital and the Alejandro
Posadas National Hospital (Bioethics Committee ‘‘Dr. Vicente
Federico del Giudice’’)
Cell culture and treatments
The human choriocarcinoma cell line BeWo was purchased
from the American Type Culture Collection (ATCC, Rockville,
MD).The human cytotrophoblastic cell line Swan-71 was gener-
ously provided by Dr. Gil Mor (Yale University School of
Medicine, New Haven, USA). They were generated by the
introduction of human telomerase reverse transcriptase, for the
immortalization of primary human cells [38,39]. BeWo and Swan-
71 trophoblastic cells were grown in 45% Dulbecco’s modified
Eagle medium (DMEM) and 45% HAM F-12 (Invitrogen)
supplemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin, 100 mg/ml streptomycin, 2 mM glutamine (Invitrogen),
and 1 mM sodium pyruvate (Sigma Chemical Company, St.
Louis, MO) at 37uC in 5% CO2.
After 24 h of plating, cell culture medium was replaced with
DMEM-F12 - 0% FBS to induce apoptosis and cells were treated
for 72 h for total protein immunoblotting or during 24h for
protein phosphorylation determinations, in the absence or
presence of different concentrations of leptin (from 5 ng/ml to
250 ng/ml). Cells cultured continuously with 10% FBS were used
as control. In experiments designed to diminish endogenous leptin
expression, an antisense oligonucleotide (AS), complementary to
the first five amino acids of leptin mRNA sequence [18] was used.
The sequence is: 59GCACAGGGTTCCCCAATGCAT39. Dif-
ferent concentrations of AS from 1 mM to 4 mM were used during
72 h incubations as reported previously [33]. Then cells were
washed with PBS and solubilized in lysis buffer (16 phosphate-
buffered saline (PBS), 1% Nonidet P-40, 0.5% sodium deoxycho-
late, 0.1% sodium dodecyl sulfate (SDS), and 10 mg/ml
phenylmethanesulfonyl fluoride (PMSF)). Cell lysates were used
for Western blot analysis.
Placental explants collection and processing
Human placentas (n = 5) were obtained after vaginal delivery
following normal term pregnancies and immediately suspended in
ice-cold PBS and transported to the laboratory, where they were
washed 2–3 times in sterile PBS to remove excess blood. Villous
tissue free of visible infarct, calcification, or hematoma was
sampled from at least five cotyledons at a distance midway
between the chorionic and basal plates. These core parts of
cotyledons were cut into multiple cubic segments (10–15 mg wet
weight) and thoroughly rinsed with cold Hanks medium pH 7.4
(137 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgSO4,
0.3 mM Na2HPO4, 0.4 mM KH2PO4, and 4 mM NaHCO3).
None of the donor patients suffered from anomalous pregnancy.
Treatments of placental explants
Placental explants for all experiments were treated only during
24 h as they represent a more physiologic model and shorter times
are needed to evidence leptin effect.
Placental explants were randomly distributed in tubes contain-
ing 1 ml of Hanks medium (n= 1 explant/tube, 4 replicates per
treatment), maintained in a shaking water bath at 37uC during
5 min to equilibrate temperature and incubated for 24 h in
DMEM-F12 0% FBS in the absence or presence of different
concentrations of leptin (from 5 ng/ml to 250 ng/ml). Explants
were removed from the bath, centrifuged for 2 min at 2000 g at
4uC and resuspended in 500 ml of lysis buffer (16 PBS, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and
10 mg/ml PMSF) during 30 min at 4uC on an orbital shaker
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and later centrifuged at 10000 g for 20 min. Supernatants were
analyzed by Western blot.
Western blot analysis
Total cell lysates were prepared in lysis buffer. The lysates were
centrifuged at 10000 g for 10 min to remove cellular debris. The
protein concentration of the supernatant was determined by the
Bradford staining method [40], with bovine serum albumin (BSA)
as standard. Lysates were mixed with Laemmli’s sample buffer
containing 2% SDS and 30 mM b-mercaptoethanol, boiled for
5 min, resolved by SDS-PAGE on a 12% gel, and electrophoret-
ically transferred to a nitrocellulose membrane (Hybond, Amer-
sham Pharmacia). Membranes were equilibrated in 16 PBS and
non-specific binding sites were blocked by 5% non-fat milk in PBS
at room temperature for 1 h. The membranes were then
immunoblotted with monoclonal mouse anti-Caspase-3 (1:1000,
Cell Signaling), monoclonal rabbit anti- leptin (1:1000, Santa
Cruz), monoclonal rabbit anti-PARP (1:100, Santa Cruz),
monoclonal mouse anti-p53 (1:1000, Santa Cruz), polyclonal
rabbit anti-phospho Ser-46 p53 (1:1000, Cell Signaling), poly-
clonal rabbit anti-BID (1:1000, Cell Signaling), polyclonal rabbit
anti-BAX (1:1000, Santa Cruz), or polyclonal rabbit anti-BCL-2
(1:1000, Epitomics). Loading controls were performed by immu-
noblotting the same membranes with polyclonal rabbit anti-b-
actin (1:1000, Santa Cruz), monoclonal mouse anti-a-tubulin
(1:2500, Santa Cruz) or monoclonal mouse anti glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (1:2500, Calbiochem). The
antibodies were detected using horseradish peroxidase-linked goat
anti-rabbit IgG (1:10000, Santa Cruz) or goat anti-mouse IgG
(1:10000, Santa Cruz) and visualized by the Amersham Pharmacia
ECL Chemiluminescence signaling system and a Bio-Imaging
Analyzer Fujifilm LAS-1000. Quantification of protein bands was
determined by densitometry using Image J 1.47 software (Wayne
Rasband National Institute of Health, USA).
DNA fragmentation assay
Apoptosis was evaluated by examining the characteristic pattern
of DNA laddering to assay DNA fragmentation. Placental explants
(40 mg of tissue per treatment) were incubated in 1 ml of DMEM-
F12 in the presence or absence of FBS containing 100 ng/ml of
leptin in a shaking water bath at 37uC. After 24 h of treatment,
placental explants were harvested, washed in PBS and homoge-
nized in 500 ml of lysis buffer containing 1% of SDS, 50 mM
EDTA, 50 mM Tris HCl and 50 mM NaCl. Then, proteinase K
(10 mg/mL) was added to the homogenates and incubated at
55uC during 2 hours. Afterwards, 5 M NaCl was added, mixed by
inversion and centrifuged at 15000 rpm for 15 min at 4uC.
Supernatants were transferred and cold ethanol was added, mixed
by inversion and the mixtures were left at 220uC overnight.
Samples were centrifuged at 15000 rpm for 15 min at 4uC and
DNA pellet was air dried and resuspended in 100 mL of sterile
water. DNA fragments were separated by a 2% agarose gel
electrophoresis at 80 V for 1.5 h. The gels were stained with
0.5 mg/ml ethidium bromide and low DNA fragments visualized
on a UV-illuminator. Quantification of low molecular weight
bands was determined by densitometry using Image J 1.47
software.
Plasmids
We used a vector derived from pGL2 with Bax promoter region
cloned upstream luciferase reporter gene (pBax-Luc). It was kindly
provided by Dr. Susana Llanos (CNIO, Madrid, Spain). To
normalize the efficiency of individual transfections, pRSV-bgal
containing the b-galactosidase gene under the control of the Rous
sarcoma virus (RSV) was used. To perform transient transfection
assays, plasmids were purified using the Midipreps Wizard kit
(Promega Co.), and DNA concentration was estimated spectro-
photometrically.
Transient transfection experiments
For transient transfection experiments, BeWo cells were plated
at a density of 2.56105 cells/ml onto six-well dishes containing
2 ml of DMEM-F12 plus 10% FBS. Cells were incubated for 24 h.
Medium was replaced and transfection of cells was performed
according to the standard liposome-mediated method. In order to
determine the sensitivity of the method in this cell type, a standard
dose of reporter plasmid vs. light emission was performed (data not
shown). Typically 5 mg of the luciferase reporter and 5 mg of
pRSV-bgal internal control construct were transfected using 5 ml
of LipofectAMINE (Life Technologies, Inc.). The medium was
replaced after 5 h with DMEM-F12 0% FBS with the addition of
the different effectors. Transfection analysis was performed by
duplicate in each of at least three independent experiments.
Assays for luciferase and b-galactosidase activities
Luciferase activity in cell lysates was measured using the
Luciferase Assay System (Promega). Cells were washed with PBS
and harvested 72 h after transfection using 50 ml of lysis buffer.
Cell extracts were centrifuged and 30 ml of the supernatant was
mixed with 50 ml of luciferase assay buffer. Luciferase activity was
measured with the GloMax-Multi+Microplate Multimode Reader
luminometer (Promega Corp). b-galactosidase activity was assayed
using 1 mg of o-nitrophenyl b-D-galactopyranoside (AmResco) as
the substrate in buffer Z (60 mM Na2HPO4, 40 mM NaH2PO4,
10 mM KCl, 1 mM MgSO4, 0.07% b-mercaptoethanol) and
incubated at 37uC until yellow staining. The product was
determined by absorption at 420 nm. This value was used to
correct variations in transfection efficiency. Luciferase results were
calculated as the ratio of luciferase activity per unit of b-
galactosidase activity. Duplicate samples were analyzed for each
data point.
Quantitative real-time RT-PCR assay
Abundance of p53 mRNA was determined by quantitative real
time RT-PCR reaction (qRT-PCR). Total RNA was extracted
from placental explants using TRISURE reagent, according to the
manufacture’s instructions (Bioline Co). Concentration and purity
of the isolated RNA were estimated by spectrophotometry at 260
and 280 nm. For cDNA synthesis, 5 mg of total RNA was reverse-
transcribed at 50uC during 1 h using the Transcriptor first Strand
cDNA synthesis Kit (Roche). Quantitative real time PCR reaction
was performed using the following primers based on the sequences
of the NCBI GenBank database: p53, forward, 59GGAAGA-
GAATCTCCGCAA39; reverse, 59AGCTCTCGGAACATCTC-
GAAG39; and cyclophilin, forward, 59CTTCCCCGA-
TACTTCA39; reverse, 59TCTTGGTGCTACCTC 39. qRT-
PCR Master Mix Reagent kit was obtained from Roche (Fast
Start universal SYBR Green) and PCR reactions were performed
on a Chromo 4 DNA Engine (BioRad). A typical reaction
contained 10 mM of forward and reverse primer, 3 ml of cDNA
and the final reaction volume was 25 ml. The reaction was initiated
by preheating at 50uC for 2 min, followed by heating at 95uC for
10 min. Subsequently, 41 amplification cycles were carried out as
follows: denaturation 15 sec at 95uC and 1 min annealing and
extension 1 min at 59uC. The threshold cycle (CT), from each well
was determined by the Opticon Monitor 3 Program. Relative
quantification was calculated using the 22DDCT method [41]. For
the treated samples, evaluation of 22DDCT indicates the fold
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change in gene expression, normalized to a housekeeping gene
(cyclophilin), and relative to the untreated control.
Data analysis
Experiments were repeated separately at least three times to
assure reproducible results. Results are expressed as the mean 6
standard deviation (S.D.). The statistical significance was assessed
by ANOVA followed by different post hoc tests indicated in each
figure and was calculated using the Graph Pad Instat computer
program (San Diego, CA). A P-value ,0.05 was considered
statistically significant.
Results
Leptin diminishes apoptosis in placental cells
We previously reported that leptin has a trophic effect in
trophoblastic JEG-3 and BeWo cells, preventing the apoptosis
promoted by serum deprivation [34]. Apoptosis was investigated
by determination of Caspase-3 activated form and cPARP by
Western blot and DNA fragmentation assay. Previously we found
that leptin prevents Caspase-3 activation in JEG-3 trophoblastic
cells involving MAPK pathway [34]. As it is shown in Figure 1A,
serum starvation signal is sufficient to increase Caspase-3
activation in BeWo cells. Treatment with leptin reduced
Caspase-3 activation in a dose dependent manner. Maximal effect
was achieved at 250 ng leptin/ml. Since BeWo cell line expresses
leptin [33], we speculated that perhaps the Caspase-3 activation
effect exerted by exogenous leptin could be partially masked by
endogenous production. To address this issue, BeWo cells were
treated with different concentrations of leptin AS. As seen in
Figure 1B, treatment with 1–4 mM AS increased Caspase-3
activation. In Figure 1C results obtained in human placental
explants, a more physiologic model, are shown. As seen, leptin
treatment lowered Caspase-3 activation. Leptin effect on late
apoptosis was determined in placental explants using a different
experimental approach, the DNA fragmentation assay. With this
technique it is possible to determine the presence of low DNA
fragments, products from apoptotic DNA cleavage. As it is seen in
Figure 1D, serum deprivation increased the apoptotic cleavage of
DNA meanwhile 100 ng leptin/ml significantly reduced low
weight population of DNA fragments.
PARP cleavage is catalyzed by activated Caspase-3 which
prevents PARP-mediated DNA repair processes. To further study
leptin effect on Caspase-3 activity, the p89 fragment of cleaved
PARP-1 (cPARP) was determined. Serum deprivation significantly
raised cPARP and treatment with leptin decreased it in
trophoblastic cells (Fig. 1E) and placental explants (Fig. 1F). Taken
together these results highlight the survival effect exerted by leptin
on placental cells.
Leptin enhances BCL-2/BAX relationship in placental cells
probably by augmenting BCL-2 expression
BCL-2 and BAX expression, an anti- and a pro- apoptotic
member of the BCL-2 family respectively, was analyzed in cell
culture (Fig. 2) and placental explants (Fig. 3) stimulated with
different leptin concentrations to further characterize apoptotic
effect of leptin in trophoblastic cells. Serum starvation reduced
BCL-2 level in Swan-71 cells measured by Western blot analysis
(Fig. 2A). Leptin treatment at 20 ng leptin/ml significantly
augmented BCL-2 levels in Swan-71 cells (Fig. 2A) and placental
explants (Fig. 3A).
Serum starvation increased BAX levels in Swan-71 cells and
placental explants (Figs. 2A and 3A). Leptin decreased BAX levels,
at least in primary placental explants, with a maximal effect at
100 ng leptin/ml (Fig. 3A). In Figures 2B and 3B it could be seen
that 20 ng leptin/ml increased BCL-2/BAX relationship. We next
analyzed the possibility that leptin might modulate BAX
expression at the transcriptional level. BeWo cells were transiently
transfected with pBax- Luc reporter construct and treated with
different leptin concentrations. As displayed in Figure 2C,
incubation of cells with serum depleted media enhanced BAX
gene expression and treatment with 50-100 ng leptin/ml signif-
icantly reduced it.
Leptin diminishes BID level in placental cells
BH3-only proteins, like BID, are essential for initiation of
apoptosis signaling, being activated transcriptionally and/or post-
transcriptionally [42]. We decided to analyze leptin effect on BID
levels in Swan-71 cells and human placental explants. As it is seen
in Figure 4A incubation of the cells with serum free media
significantly enhanced BID expression. The treatment with leptin
significantly decreased Bid expression. Maximum effect was
achieved with a leptin dose of 100 ng/ml. Similar results were
obtained when BID expression was determined in human
placental explants (Fig. 4B).
Leptin diminishes p53 level in trophoblastic cells and
placental explants
The tumor suppressor p53 is best characterized as a transcrip-
tion factor that binds to specific DNA sequences and transactivates
a number of genes with a variety of functions including cell cycle
Figure 1. Leptin prevents apoptosis in placental cells. Caspase activity was determined in BeWo cells (A and B) or placental explants (C). A–B)
BeWo (16106 cells) were plated in complete DMEM-F12 media (10% FBS). After 24 h cells were incubated during 72 h in DMEM-F12 0% FBS, with
increasing doses of leptin (A) or an oligonucleotide complementary to leptin sequence (AS) (B), as indicated in the figure. Cell extracts were prepared
as indicated in Materials and Methods and proteins were separated on SDS-PAGE gels. The inset shows representative blots and quantification
confirming reduced leptin expression in AS treated cells. C) Placental explants were processed as described in Material and Methods and incubated in
DMEM-F12 0% FBS media supplemented with increasing leptin doses during 24 h. Placental extracts were prepared and proteins were separated on
SDS-PAGE gels. Caspase-3 cleaved fragment was determined by Western blot analysis (A, B and C). D) Gel electrophoresis of apoptotic DNA
fragmentation. Inspection of electrophoretic profiles revealed a lower ladder formation in presence of leptin. Quantification of low molecular weight
bands is shown. DNA fragmentation assay was performed as indicated in Materials and Methods. E) Swan-71 cells (16106 cells) were plated in
complete DMEM-F12 media (10% FBS). After 24 h cells were incubated during 72 h in DMEM-F12 0% FBS, with increasing doses of leptin as indicated
in the figure. Cell extracts were prepared as indicated in Materials and Methods and proteins were separated on SDS-PAGE gels. F) Placental explants
were processed as described in Material and Methods and incubated in DMEM-F12 0% FBS media supplemented with increasing leptin doses during
24 h. Placental extracts were prepared and proteins were separated on SDS-PAGE gels. In both cases (E and F) cleaved PARP (cPARP) fragment was
determined by Western blot analysis. Cells cultured with DMEM-F12 media supplemented with 10% FBS were used as control. Molecular weights
were estimated using standard protein markers. Molecular mass (kDa) is indicated at the right of the blot. Loading controls were performed by
immunoblotting the same membranes with anti-b-actin, anti-a-tubulin or anti-GAPDH. Bands densitometry is shown in lower panels. Results are
expressed as mean 6 SD for three independent experiments. Statistical analyses were performed by ANOVA and Bonferroni’s multiple comparison
post hoc test, relative to FBS 10% (#) or FBS 0% (*). # p,0.05, ###p,0.001, * p,0.05, ** p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0099187.g001
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arrest, apoptosis, and others [43]. To determine if leptin modifies
p53 levels in trophoblastic Swan-71 cells, p53 expression was
analyzed. Serum starvation induced p53 both at mRNA and
protein levels (Fig. 5). Leptin treatment significantly reduced p53
protein levels. Maximum effect was achieved at doses of 100 ng/
ml (Figure 5A). Human placental explants were also analyzed. As
it is shown in Figure 5B, leptin significantly diminished p53 protein
levels in a dose dependent manner. Maximum effect was achieved
with a dose of 100 ng/ml of leptin. Real time PCR assay was
performed to determined leptin effect on p53 mRNA levels, in
placental explants. Leptin treatment in serum free media showed a
Figure 2. Leptin enhances BCL-2/BAX relationship in placental cells. A) Swan-71 cells (16106 cells) were plated in DMEM-F12 media in the
absence of serum and incubated during 72 h with different doses of leptin. DMEM-F12 10% FBS was used as a control. Cell extracts were prepared as
indicated in Materials and Methods. Proteins were separated on SDS-PAGE gels and BCL-2 and BAX expression was determined by Western blot
analysis. Molecular weights were estimated using standard protein markers. Molecular mass (kDa) is indicated at the right of the blot. Loading
controls were performed by immunoblotting the same membranes with anti-a-tubulin. Bands densitometry is shown in lower panels, results are
expressed as mean 6 SD for three independent experiments. B) Leptin increased BCL-2/BAX relationship. C) BeWo cells were transiently transfected
with a plasmid containing a section of BAX promoter (pBax-Luc). After transfection, cells were incubated for 72 h in DMEM-F12 and treated with
increasing leptin doses. Cell extracts were prepared as indicated in Materials and Methods and Luciferase activity was normalized to b-galactosidase
activity. Activity obtained in the absence of leptin and pBax-Luc was set as control. Statistical analyzes were performed by ANOVA. Asterisks indicate
significant differences from the control according to Bonferroni’s multiple comparison post hoc test, relative to FBS 10% (#) or FBS 0% (*). ## p,
0.01, * p,0.05, *** p,0.001.
doi:10.1371/journal.pone.0099187.g002
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significant dose-dependent reduction of p53 mRNA level
(Figure 5C).
Leptin diminishes p53 Ser-46 phosphorylation in
trophoblastic cells and placental explants
The phosphorylation at Ser-46 was shown to be involved in the
regulation of apoptosis. We decided to evaluate the effect of leptin
on the phosphorylation of p53 Ser-46. As it is shown in Figure 6A,
the absence of serum slightly increased the phosphorylation of Ser-
46 in p53. Treatment with leptin significantly decreased the
phosphorylation of Ser-46 of p53 with a maximal effect achieved
with a leptin dose of 100 ng/ml. Also in human placental explants
(Fig. 6B), 100 ng leptin/ml significantly decreased the phosphor-
ylation of p53 Ser-46.
Figure 3. Leptin enhances BCL-2/BAX relationship in human placental explants. A) Placental explants were processed as described in
Materials and Methods and incubated during 24 h in DMEM-F12 media supplemented with increasing leptin doses. DMEM-F12 10% FBS was used as
control. Placental extracts were prepared and proteins were separated on SDS-PAGE gels. BCL-2 and BAX expression were determined by Western
blot analysis as indicated in the Figure. Molecular weights were estimated using standard protein markers. Molecular mass (kDa) is indicated at the
right of the blot. Loading controls were performed by immunoblotting the same membranes with anti-a-tubulin. Bands densitometry is shown in
lower panels, results are expressed as mean 6 SD for three independent experiments. B) BCL-2/BAX relationship is shown. Statistical analyzes were
performed by ANOVA. Asterisks indicate significant differences from the control according to Bonferroni’s multiple comparison post hoc test, relative
to FBS 0% (*). * p,0.05, ** p,0.01
doi:10.1371/journal.pone.0099187.g003
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Discussion
The programmed cell death or apoptosis is an essential process
for normal placental development but is highly increased in
placental diseases as hydatidiform mole, pre-eclampsia and intra-
uterine growth restriction (IUGR) [44]. During normal pregnancy,
trophoblast apoptosis increases while placenta grows. As mono-
nucleated villous trophoblast cells proliferate, some daughter cells
differentiate and fuse forming the syncytiotrophoblast. The
maintenance and integrity of the syncytial layer depend on the
continuous input of new material. Old and no longer needed
cellular material is shed from the apical surface of the syncytio-
trophoblast and released into the maternal circulation as apoptotic
syncytial knots [45].
Trophoblast apoptosis, as other types of cell apoptosis, includes
the extrinsic and intrinsic pathways culminating in the activation
of caspases. The formation of apoptotic bodies and liberation of
this material into the maternal circulation was demonstrated and
may be detected in maternal circulation during the course of
normal gestation [44]. Even though placental apoptosis is a
normal process during pregnancy it may be initiated by different
damaging stimuli, including hypoxia and oxidative stress [46].
Excessive placental trophoblast apoptosis and shedding of placenta
debris are associated with different placental-insufficiency-related
pregnancy’s complications, and some molecular biomarkers are
being studied for their potential in diagnosis of these pathologies
[47]. It is postulated that placental-derived material might induce
maternal endothelial dysfunction of pre-eclampsia [48]. Wide-
spread apoptosis of the syncytiotrophoblast may also impair
trophoblast function leading to the reduction in nutrient transport
seen in IUGR.
However, during normal pregnancy, extravillous trophoblast
cells invade maternal uterine tissues. The interstitial trophoblast
penetrates decidual tissues reaching the inner third of the
myometrium. A subset of the interstitial trophoblast, transforms
uterine spiral arteries into large-bore conduits to enable the
adequate supply of nutrients and oxygen to the placenta and thus
to the fetus. Controlled invasion by trophoblast of uterine decidua,
myometrium and spiral arteries, is essential for normal fetopla-
cental development. The balance between trophoblast apoptosis
and proliferation represents a mechanism to control normal
trophoblast invasion [49]. In this regard leptin, was described as
an important cytokine regulating trophoblast survival, promoting
growth and preventing the apoptotic process [33]. These effects
may be of physiological relevance since trophoblastic cells are an
important source of increased leptin production during pregnancy
[23], [32]. Moreover, leptin levels are increased under stressful
condition for placenta cells such as preeclampsia or gestational
diabetes [32,50]. This overproduction of leptin may be helpful to
prevent the stress-mediated apoptosis of the trophoblastic cells.
However, little is known about the molecular mechanisms
underlying these effects. Leptin activation of MAPK pathway
has been previously found to be the mechanism whereby leptin
promotes cell survival preventing apoptosis [51,52]. In tropho-
blastic JEG-3 cells we have found that leptin prevents the
apoptotic process triggered by the deprivation of serum by means
of the activation of MAPK pathway [34], but little is known about
the mechanisms involved.
In this study, we employed BeWo human choriocarcinoma cells
and Swan-71 cells. Human placental explants from healthy donors
were also studied to confirm the physiological relevance of the
Figure 4. Leptin diminishes BID level in placenta. A) Swan-71 cells (16106 cells) were plated in DMEM-F12 media 10% FBS. After 24 h, cells
were incubated during 72 h with increasing doses of leptin in DMEM-F12 0% FBS. Cell extracts were prepared as indicated in Materials and Methods
and proteins were separated on SDS-PAGE gels. B) Placental explants were processed as described in Material and Methods and incubated in DMEM-
F12 0% FBS media supplemented with increasing leptin doses during 24 h. Placental extracts were prepared and proteins were separated on SDS-
PAGE gels. In both cases (A and B) BID cleaved fragment was determined by Western blot analysis. DMEM-F12 10% FBS was used as control.
Molecular weights were estimated using standard protein markers. Molecular mass (kDa) is indicated at the right of the blot. Loading controls were
performed by immunoblotting the same membranes with anti-a-tubulin or anti-b-actin. Bands densitometry is shown in lower panels. Results are
expressed as mean6 SD for three independent experiments. Statistical analyzes were performed by ANOVA. Asterisks indicate significant differences
from the control according to Bonferroni’s multiple comparison post hoc test, relative to FBS 10% (#) or FBS 0% (*). ## p,0.01, * p,0.05, ** p,0.01
doi:10.1371/journal.pone.0099187.g004
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mechanisms involved in leptin survival effect. BeWo cells maintain
many characteristics of human trophoblast cells and have been
widely used to study placental function [53]. Swan-71 cell line has
attributes that are characteristic of primary first trimester
trophoblast cells. The Swan-71 cells are positive for the expression
of cytokeratin 7, vimentin and HLA-G and exhibit a cytokine and
growth factor profile that is similar to primary trophoblast cells
[38]. Swan-71 cells also express the long isoform of leptin receptor
(unpublished results). They represent a valuable model for in vitro
trophoblast studies. In this study we confirmed that leptin
diminishes apoptosis in placental cells by virtue of the decrease
of the Caspase-3 activation both in BeWo cells and in human
placental explants. Moreover, when endogenous leptin expression
was inhibited using an oligonucleotide complementary to leptin
mRNA, cleaved Caspase-3 peptide increased. Leptin also dimin-
ished the cleavage of PARP, a nuclear DNA-binding protein that
Figure 5. Leptin reduces p53 levels in placenta. A) Swan-71 cells (16106 cells) were plated in DMEM-F12 media in the absence of serum and
incubated during 72 h with different leptin concentrations. Cell extracts were prepared as indicated in Materials and Methods and proteins were
separated on SDS-PAGE gels. B) Placental explants were processed as described in Material and Methods and incubated in DMEM-F12 media
supplemented with increasing leptin doses during 24 h. Placental extracts were prepared and proteins were separated on SDS-PAGE gels. In both
cases (A and B) p53 was determined by Western blot analysis. DMEM-F12 10% FBS was used as a control. Molecular weights were estimated using
standard protein markers. Molecular mass (kDa) is indicated at the right of the blot. Loading controls were performed by immunoblotting the same
membranes with anti-a-GAPDH. Bands densitometry is shown in lower panels. Results are expressed as mean 6 SD for three independent
experiments. C) p53 expression in human placental explants was determined by qRT-PCR. RNA was extracted as described in Materials and Methods.
Statistical analyzes were performed by ANOVA. Asterisks indicate significant differences from the control according to Bonferroni’s multiple
comparison post hoc test, relative to FBS 10% (#) or FBS 0% (*). # p,0.05, ## p,0.01, * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0099187.g005
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influences DNA repair, DNA replication, modulation of chroma-
tin structure and apoptosis. These results reinforced the notion of
leptin as a survival factor. By a different experimental approach,
we found that leptin treatment reduced the presence of small
fragments product of DNA cleavage. These data prompted us to
study the mediators that could be involved in placental cell
apoptosis.
It is well known that BCL-2-family proteins are central
regulators of cell life and death. The first pro-apoptotic member
of the family, BAX (BCL-2 Antagonist X) was identified as a BCL-
2-interacting protein that opposed BCL-2 and promoted apoptotic
cell death [54]. Subsequent data led to the identification of more
pro-apoptotic proteins that contain several conserved regions of
sequence similarity including BAX, BAK, and BOK. A variety of
genetic and biochemical studies argue that these multidomain
proteins are the effectors of the mitochondrial cell death pathway,
with anti-apoptotic proteins such as BCL-2 and BCL-xL operating
as upstream regulators that oppose the intrinsic death-inducing
actions at mitochondrial membranes [55]. We observed that leptin
increased the relation BCL-2/BAX both in Swan-71 and human
placental explants. The modulation of these ratios by leptin was
due principally to an increase in BCL-2 protein. Our data showed
also a reduction of BAX protein in placental explants. Similar
results were observed in lymphocytes B. Leptin promotes B-cell
homeostasis by inhibiting apoptosis through the activation of
expression of BCL-2 and inhibits the expression of the pro-
apoptotic BCL-2 family proteins, BAX, BIM, and BAD [56]. An
upregulation of the BCL-xL gene was also seen in lymphocytes
treated with leptin, suggesting that leptin might contribute to the
recovery of immune suppression by inhibiting lymphocyte
apoptosis [57]. We demonstrated that leptin represses BAX
expression at the transcriptional level in BeWo cells as seen by
transient transfection reporter assay, suggesting that mechanisms
of regulation of gene BAX expression could be involved. We
observed that after leptin treatment, BAX protein remained
unchanged in Swan-71 cells. The discrepancy observed on leptin
effect on BAX expression between BeWo and placental explants
and Swan-71 cells might be due to differences in the gestational
age of these models. Further studies are in progress at our lab to
clarify this fact. The major finding of this study is the increase of
BCL-2/BAX ratio caused by leptin. It was reported that an
increase of BCL-2 protein might influence the level of BAX
protein, but the mechanisms are still under debate. In this report,
upon apoptosis induction by IL-3 withdrawal, the over-expression
of BCL-2 maintained the high levels of mitochondrial BAX
content but Cytochrome c release was nevertheless inhibited [58].
This could explain the unchanged BAX expression in Swan-71
cells, when BCL-2 is augmented by leptin treatment.
3D solution structure of BAX in the soluble inactive state
indicates that the C-terminal membrane anchoring domain is
tucked into the same pocket that binds BH3 peptides. In response
to defined signals, BAX and BAK are activated and oligomerize,
exposing its C-terminal membrane-anchoring domain, and
inserting into mitochondrial membranes [59]. In the classical
model, the anti-apoptotic members of the family such as BCL-2 or
BCL-xL inhibit BAX and BAK activation through a direct
interaction involving the so called BH domains (the BCL-2
homology domains, which define both the structural and the
functional homology patterns within the BCL-2 family). In this
model, BAX activation is favored by the pro-apoptotic BH3-only
Figure 6. Leptin reduces Ser-46 p53 phosphorylation level in placenta. A) Swan-71 cells (16106 cells) were plated in DMEM-F12 10% FBS.
After 24 h cells were incubated during 24 h with increasing doses of leptin in DMEM-F12 in the absence of serum. Cell extracts were prepared as
indicated in Materials and Methods and proteins were separated on SDS-PAGE gels. B) Placental explants were processed as described in Material and
Methods and incubated in DMEM-F12 0% FBS media supplemented with increasing leptin doses during 24 h. DMEM-F12 10% FBS was used as a
control. Placental extracts were prepared and proteins were separated on SDS-PAGE gels. In both cases (A and B) Phospho Ser-46 p53 was
determined by Western blot analysis. DMEM-F12 media supplemented with 10% FBS was used as control. Molecular weights were estimated using
standard protein markers. Molecular mass (kDa) is indicated at the right of the blot. Loading controls were performed by immunoblotting the same
membranes with anti-GAPDH. Bands densitometry is shown in lower panels. Results are expressed as mean6 SD for three independent experiments.
Statistical analyzes were performed by ANOVA. Asterisks indicate significant differences from the control according to Bonferroni’s multiple
comparison post hoc test, relative to FBS 10% (#) or FBS 0% (*). ## p,0.01 * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0099187.g006
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proteins. These proteins can act both as direct activators of BAX
as BID, BIM or PUMA, or as de-repressors as BAD, NOXA that
interact with anti-apoptotic members of the BCL-2 family [60]. In
this work we could demonstrate that leptin treatment decreases
BID protein. All these results consolidate the anti-apoptotic role of
leptin in placental cells.
It was demonstrated that the human BAX gene promoter
contains typical p53-binding sites and is transcriptionally upregu-
lated by p53[12]. The p53 tumor suppressor protein is a key
component of cellular mechanisms that are activated by cellular
stresses [61]. Therefore, we investigated whether this key cell
cycle-signaling protein was involved in the effect of leptin. We
determined p53 expression in the presence or absence of leptin in
a model of serum deprivation condition, both in Swan-71 and
human placental explants. A significant decrease of p53 was
observed in both models demonstrating that leptin regulates p53
level under stress. Under normal conditions, p53 is a short-lived
protein that is highly regulated and maintained at low or
undetectable levels. After stress, such us serum deprivation, p53
is activated mostly at the post-translational level by a complex
series of modifications that include the phosphorylation and
acetylation of specific residues in the amino-terminal and carboxy-
terminal domains. In addition to post-translational modifications,
protein–protein interactions and subcellular relocalization also
have a role in the activation of p53 [62]. The activation of p53
leads to the transcription of several genes whose products trigger
different biological outcomes (for example, cell cycle arrest,
apoptosis, DNA repair, replicative senescence or differentiation).
MDM2 is known to negatively regulate p53 by mediating its
ubiquitination and subsequent degradation in the proteasome.
Little is known about leptin effect on MDM2 levels, but we
speculate that leptin might regulate MDM2 expression, triggering
the degradation of p53. Our data demonstrated that leptin not
only decreases p53 protein level but also p53 mRNA level,
measured by qRT-PCR. These results will be further explore,
studying the mechanisms by which leptin regulates p53 expression.
Not all of the pathways involved in the processes regulated by
p53 are known but phosphorylation of p53 at Ser-46 was shown to
be involved in the regulation of apoptosis after DNA damage.
Moreover, there is evidence that Ser-46 of p53 is phosphorylated
in response to DNA damage in vivo, and it plays a pivotal role for
apoptotic signaling by p53 through regulating the transcriptional
activation of an apoptosis-inducing gene, p53AIP1 [10]. We
decided to study the effect of leptin on this post-translational
modification. Our data demonstrated that leptin significantly
diminishes Ser-46 of p53 under stress condition. All these results
confirmed the involvement of p53 regulation in leptin anti-
apoptotic effect.
Our findings provide evidence for an inhibitory effect of leptin
on the cell apoptosis program, suggesting a trophic role of leptin in
the physiology of trophoblast cells. In addition, we have provided
some evidence for the possible anti-apoptotic mechanisms of the
leptin produced by trophoblastic cells. However, further
additional studies are needed to fully explain the effect of leptin
on the regulation of BCL-2, BAX and p53 expression. More
precisely, we have demonstrated the autocrine anti-apoptotic
effect of leptin in trophoblastic cells, providing new insights into
the functions of leptin in placental apoptosis. Since apoptosis plays
a central role in placental physiology, our work further support the
importance of leptin in human placenta.
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